Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
How Cencora Inc’s (COR) Growth ‘Slowdown’ Is Spooking Investors, But GLP-1 Demand Tells a Different Story!
Cencora began FY26 with solid operational momentum, delivering adjusted operating income growth of 12% year over year and reinforcing the durability of its pharma distribution and specialty services model. The U.S. Healthcare Solutions segment was the primary driver, with operating profit rising 21% despite the loss of a large oncology customer, highlighting the resilience of specialty channels and the growing contribution from its physician-services strategy. Gross profit increased 18% with margins expanding to 3.48%, supported by the full-quarter contribution from Retina Consultants of America and continued growth in specialty therapeutics. Management raised full-year operating income growth guidance to 11.5–13.5% while maintaining EPS guidance of $17.45–$17.75, signaling confidence in sustained execution even as interest expense remains elevated and buybacks are temporarily paused. Strategic momentum is increasingly tied to its MSO platform, with OneOncology and RCA expanding Cencora’s footprint across physician services, clinical trials infrastructure, and revenue cycle support. Meanwhile, GLP-1 therapies generated more than $1 billion in incremental demand and accounted for a meaningful share of U.S. distribution growth, underscoring durable specialty utilization trends. Although international operating income declined due to temporary pricing adjustments, underlying demand remains stable. As specialty therapeutics and physician-aligned platforms expand, can Cencora convert its MSO ecosystem and GLP-1 distribution tailwinds into sustained margin expansion and long-term earnings acceleration?

